summary
Introduced
12/09/2019
12/09/2019
In Committee
12/19/2019
12/19/2019
Crossed Over
Passed
Dead
12/31/2020
12/31/2020
Introduced Session
116th Congress
Bill Summary
Establishes and modifies several requirements to address prescription drug prices under Medicare, Medicaid, and other programs. The bill generally limits payment amounts for drugs and biologics under Medicare medical services, reduces cost-sharing under the Medicare prescription drug benefit, modifies certain authorities and requirements under the Medicaid Drug Rebate Program, revises provisions relating to regulatory approval and commercial availability of generics and biosimilars, and establishes several reporting requirements for drug manufacturers with respect to drug prices.
AI Summary
This bill establishes and modifies several requirements to address prescription drug prices under Medicare, Medicaid, and other programs. The key provisions of the bill are:
- It limits payment amounts for drugs and biologics under Medicare medical services, reduces cost-sharing under the Medicare prescription drug benefit, and modifies certain authorities and requirements under the Medicaid Drug Rebate Program.
- It revises provisions relating to regulatory approval and commercial availability of generics and biosimilars, including actions for delays and changes to the 180-day exclusivity period.
- It establishes several reporting requirements for drug manufacturers with respect to drug prices, including requirements to report on explanation for price increases and make certain drug pricing information publicly available.
- It includes provisions related to over-the-counter drug regulation, including establishing an administrative order process, and imposes user fees on over-the-counter monograph drug facilities and orders.
- It makes changes to Medicare Part D, including redesigning the benefit structure, establishing a monthly cap on beneficiary costs for insulin products, and allowing certain enrollees to spread out cost-sharing.
- It includes various other provisions related to Medicaid, the FDA, and Medicare, such as requirements for pharmacy quality measures, coordination between FDA and CMS, and waiving Medicare coinsurance for colorectal cancer screening tests.
Committee Categories
Business and Industry, Government Affairs, Health and Social Services
Sponsors (148)
Greg Walden (R)*,
Ralph Abraham (R),
Robert Aderholt (R),
Rick Allen (R),
Mark Amodei (R),
Kelly Armstrong (R),
Jodey Arrington (R),
Brian Babin (R),
Don Bacon (R),
Jim Baird (R),
Troy Balderson (R),
Jim Banks (R),
Andy Barr (R),
Jack Bergman (R),
Gus Bilirakis (R),
Dan Bishop (R),
Mike Bost (R),
Kevin Brady (R),
Mo Brooks (R),
Susan Brooks (R),
Vern Buchanan (R),
Larry Bucshon (R),
Ted Budd (R),
Tim Burchett (R),
Michael Burgess (R),
Bradley Byrne (R),
Buddy Carter (R),
John Carter (R),
Steve Chabot (R),
Liz Cheney (R),
Tom Cole (R),
Doug Collins (R),
James Comer (R),
K. Michael Conaway (R),
Paul Cook (R),
Rick Crawford (R),
Dan Crenshaw (R),
John Curtis (R),
Rodney Davis (R),
Scott DesJarlais (R),
Mario Diaz-Balart (R),
Jeff Duncan (R),
Neal Dunn (R),
Ron Estes (R),
Drew Ferguson (R),
Bill Flores (R),
Virginia Foxx (R),
Russ Fulcher (R),
Greg Gianforte (R),
Bob Gibbs (R),
Anthony Gonzalez (R),
Lance Gooden (R),
Kay Granger (R),
Garret Graves (R),
Mark Green (R),
Morgan Griffith (R),
Glenn Grothman (R),
Michael Guest (R),
Brett Guthrie (R),
James Hagedorn (R),
Andy Harris (R),
Vicky Hartzler (R),
Kevin Hern (R),
Jaime Herrera Beutler (R),
Jody Hice (R),
French Hill (R),
George Holding (R),
Richard Hudson (R),
Bill Huizenga (R),
Will Hurd (R),
Bill Johnson (R),
Dusty Johnson (R),
Dave Joyce (R),
John Joyce (R),
John Katko (R),
Fred Keller (R),
Mike Kelly (R),
Peter King (R),
Adam Kinzinger (R),
David Kustoff (R),
Darin LaHood (R),
Doug LaMalfa (R),
Bob Latta (R),
Billy Long (R),
Blaine Luetkemeyer (R),
Kenny Marchant (R),
Roger Marshall (R),
Michael McCaul (R),
David McKinley (R),
Cathy McMorris Rodgers (R),
Dan Meuser (R),
Carol Miller (R),
Paul Mitchell (I),
John Moolenaar (R),
Alex Mooney (R),
Markwayne Mullin (R),
Greg Murphy (R),
Dan Newhouse (R),
Ralph Norman (R),
Devin Nunes (R),
Pete Olson (R),
Gary Palmer (R),
Greg Pence (R),
Scott Perry (R),
Tom Reed (R),
Guy Reschenthaler (R),
Tom Rice (R),
Denver Riggleman (R),
Martha Roby (R),
David Roe (R),
Hal Rogers (R),
David Rouzer (R),
John Rutherford (R),
Steve Scalise (R),
David Schweikert (R),
Austin Scott (R),
F. James Sensenbrenner (R),
John Shimkus (R),
Mike Simpson (R),
Adrian Smith (R),
Chris Smith (R),
Jason Smith (R),
Lloyd Smucker (R),
Ross Spano (R),
Pete Stauber (R),
Elise Stefanik (R),
Bryan Steil (R),
Greg Steube (R),
G.T. Thompson (R),
Mac Thornberry (R),
William Timmons (R),
Mike Turner (R),
Fred Upton (R),
Ann Wagner (R),
Tim Walberg (R),
Jackie Walorski (R),
Michael Waltz (R),
Steve Watkins (R),
Randy Weber (R),
Daniel Webster (R),
Brad Wenstrup (R),
Bruce Westerman (R),
Roger Williams (R),
Joe Wilson (R),
Rob Wittman (R),
Steve Womack (R),
Ron Wright (R),
Lee Zeldin (R),
Last Action
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law. (on 12/19/2019)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
Document Type | Source Location |
---|---|
State Bill Page | https://www.congress.gov/bill/116th-congress/house-bill/19/all-info |
BillText | https://www.congress.gov/116/bills/hr19/BILLS-116hr19ih.pdf |
Bill | https://www.congress.gov/116/bills/hr19/BILLS-116hr19ih.pdf.pdf |
Loading...